ALK and non-small cell lung carcinoma: ALK protein kinase inhibitors greatly improve the prognosis of patients with ALK‐positive NSCLC,18 and it has been noted in the clinic that patients with seemingly positive ALK fusion genes are more likely to develop brain metastases.